Login to Your Account

Other News To Note

Tuesday, March 5, 2013
Amicus Therapeutics Inc., of Cranbury, N.J., said it introduced chaperone-advanced replacement therapy (CHART) as the brand name for its technology platform that combines pharmacological chaperones with enzyme replacement therapy or lysosomal storage diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription